



The effect of truncation on prion-like properties of α -synuclein

Received for publication, January 12, 2018, and in revised form, July 15, 2018. Published, Papers in Press, July 20, 2018, DOI 10.1074/jbc.RA118.001862

Makoto Terada^{‡S1}, Genjiro Suzuki[‡], Takashi Nonaka[‡], Fuyuki Kametani[‡], Akira Tamaoka^S, and Masato Hasegawa^{‡2}

From the [‡]Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science, 2-1-6 Kamikitazawa, Setagaya-ku, Tokyo, 156-8506, Japan and ^SDepartment of Neurology, Faculty of Medicine, University of Tsukuba, 1-1-1 Tennodai, Tsukuba, Ibaraki, 305-8575, Japan

Edited by Paul E. Fraser

Increasing evidence suggests that α -synuclein (α S) aggregates in brains of individuals with Parkinson's disease and dementia with Lewy bodies can spread in a prion-like manner. Although the initial α S nuclei are pivotal in determining α S fibril polymorphs and resulting phenotypes, it is not clear how the initial fibril seeds are generated. Previous studies have shown that α S truncation might have an important role in α S aggregation. However, little is known about how this truncation influences α S's propagation properties. In the present study, we generated α S fibrils from a series of truncated human α S constructs, characterized their structures and conformational stabilities, and investigated their ability to convert the conformation of full-length α S *in vitro*, in cultured cells, and in WT mice. We show that both C- and N-terminal truncations of human α S induce fibril polymorphs and exhibit different cross-seeding activities. N-terminally 10- or 30-residue-truncated human α S fibrils induced more abundant α S pathologies than WT fibrils in mice, whereas other truncated fibrils induced less abundant pathologies. Biochemical analyses of these truncated fibrils revealed that N-terminal 10- or 30-residue truncations of human α S change the fibril conformation in a manner that increases their structural compatibility with WT mouse α S fibrils and reduces their stability. C-terminally 20-residue-truncated fibrils displayed enhanced seeding activity *in vitro*. Our findings imply that truncation of α S can influence its prion-like pathogenicity, resulting in phenotypic diversity of α -synucleinopathies.

Misfolding and aggregation of normally soluble proteins are common pathological features of many neurodegenerative diseases (1). α -Synucleinopathies, including Parkinson's disease

(PD)³, dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) are associated with formation of abnormal aggregates of α -synuclein (α S), a natively unfolded 14-kDa protein consisting of 140 amino acids. These diseases are neuropathologically characterized by the deposition of filamentous α S aggregates with cross- β structure (2), which are abnormally phosphorylated (3) and partially ubiquitinated (4). α S and various other neurodegenerative disease-related proteins, including β -amyloid (A β), tau, and TAR-DNA-binding protein-43 (TDP-43), can propagate through neural networks in a similar manner to abnormal prion proteins in prion diseases, in which abnormal insoluble protein acts as a seed or template for converting soluble protein to abnormal form (5, 6). Although *in vitro* (7, 8) and *in vivo* (9–11) experiments using detergent-insoluble fraction of diseased brains and aggregated recombinant proteins as seeds have provided support for the “prion-like propagation hypothesis,” it is not yet clear how α S aggregates propagate through the diseased brain.

In MSA, α S is mainly deposited in glial cells, whereas α S aggregates are found in neuronal cells in PD and dementia with Lewy bodies (DLB) (12). Such phenotypic differences suggest the existence of different “strains” of pathogenic α S, whose aggregate structures determine clinical phenotypes, as in prion diseases (13, 14). Although the differences in cross-seeding activity between MSA and PD brain extracts in heterozygous mice transgenic for A53T human α S suggest that structural differences exist (11, 15), the mechanisms that cause such structural variations among sporadic α -synucleinopathies remain unclear.

In Lewy bodies, not only full-length (FL), but also truncated α S is accumulated (16). Truncation is a common posttranslational modification that is not specific to the diseased brain, and about 15% of α S is truncated even in the brain of healthy individuals (17). In the diseased brain, both N-terminally and C-terminally truncated α S species are present (18). Overexpression of truncated α S or coexistence of truncated and FL α S can enhance aggregation and neurodegeneration both *in vitro* (19, 20) and *in vivo* (21, 22). Although it has been suggested that

This work was supported by Ministry of Education, Culture, Sports, Science, and Technology Grants-in-Aid for Scientific Research (KAKENHI) Grant JP26117005 (to M. H.), Japan Society for the Promotion of Science Grants-in-Aid for Scientific Research (KAKENHI) Grant JP23228004 (to M. H.), and Japan Agency for Medical Research and Development (AMED) Grant-in-Aid for research on Brain Mapping by Integrated Neurotechnologies for Disease Studies (Brain/MINDS) Grant JP14533254 (to M. H.). The authors declare that they have no conflicts of interest with the contents of this article.

This article contains Figs. S1–S3.

¹ To whom correspondence may be addressed. Tel./Fax: 81-3-6834-2349; E-mail: mterada-tuk@umin.ac.jp.

² To whom correspondence may be addressed. Tel./Fax: 81-3-6834-2349; E-mail: hasegawa-ms@igakuken.or.jp.

³ The abbreviations used are: PD, Parkinson's disease; α S, α -synuclein; MSA, multiple system atrophy; Hu, human; Mo, mouse; FL, full-length; FLA, seeded full-length α S aggregates; TEM, transmission electron microscopy; ThT, thioflavin T; PK, proteinase K; CBB, Coomassie Brilliant Blue; Str, striatum; SN, substantia nigra; Amy, amygdala; ACC, anterior cingulate cortex; buffer A, 50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM DTT; NAC, non-amyloid- β component.




Figure 1. Human WT and truncated α S fibril seeds. A, schematic representation of the human WT and truncated α S variants used in this study. The shaded portion indicates the reported core region (residues 31–109) of WT α S fibrils. B, CBB staining of purified α S proteins. C, negative staining TEM images of WT and truncated α S fibrils. Scale bars, 100 nm. D, aggregation kinetics of human FL α S monomers under quiescent conditions in the absence or presence of 1 mol % human WT or truncated α S fibril seeds, monitored by ThT fluorescence. Curves are averages of three samples. The α S concentration was 150 μ M in all experiments.

truncation has an important influence on α S aggregation (19, 23, 24), very few studies have focused on the effect of truncation on prion-like propagation.

In the present study, we systematically investigated the structural polymorphism of truncated α S fibrils and examined whether or not these fibrils can act as templates for FL α S aggregation, using *in vitro* and *in vivo* experimental models. We found that differently truncated human α S fibrils exhibit a variety of cross-seeding activities *in vitro* and *in vivo*. Our results imply that truncation of α S in the initial nucleation phase might not only influence aggregation, but also result in phenotypic diversity.

Results

Fibril formation from truncated α S proteins

To investigate the effects of C- and N-terminal truncations on α S aggregation, we prepared a series of wildtype (WT) and truncated human α S (Fig. 1A). The constructs were expressed in *Escherichia coli*, and the purified soluble α S proteins were analyzed by SDS-PAGE (Fig. 1B). After agitation in the presence of 150 mM KCl, the formation of fibrillar aggregates was confirmed by negative-staining transmission electron microscopy (TEM) (Fig. 1C). The fibrils were 6–10 nm in

Truncation induces α -synuclein fibril polymorphs

diameter and did not branch. In agreement with a previous report (25), human C-terminally truncated α S fibrils (Δ C20 and Δ C30) tended to be shorter than WT fibrils and were bundled laterally, whereas human N-terminally truncated α S formed long fibrils similar to WT fibrils (26). These fibrils bound to thioflavin T (ThT), which is commonly used to detect amyloid formation, and showed enhanced fluorescence (Fig. S1).

To examine whether these truncated α S fibrils could act as seeds for FL α S aggregation, seeding assay against human WT α S monomer was performed by incubation under quiescent conditions in the presence or absence of 1 mol % of preformed human α S fibril seeds *in vitro* (Fig. 1D). WT and all truncated α S fibrils induced the aggregation of FL α S protein, but the ThT fluorescence was not increased in the absence of α S fibril seeds. We found that Δ C20 seeds drastically increased the rate of fibril assembly ($t_{1/2} = 2 \pm 0$ h), compared with WT seeds ($t_{1/2} = 26 \pm 6$ h). Δ N10 seeds and Δ N30 also induced fibril assembly, but more slowly ($t_{1/2} = 76 \pm 3$ and 58 ± 1 h, respectively).

Effect of truncation on induction of phospho- α S pathology in WT mice

To examine the cross-seeding activity of human truncated α S fibril seeds in WT mouse brain, we injected 750 pmol human WT and truncated α S fibril seeds into the right striatum of WT mice. Three months after injection, paraffin-embedded brain sections were prepared and immunostained with anti-phospho- α S antibody (pSer-129/EP1536Y) (Fig. 2, A and B). In mice injected with WT seeds, Lewy body/Lewy neurite-like phospho- α S aggregates were distributed bilaterally through the brain, including striatum (Str), substantia nigra (SN), amygdala (Amy), and anterior cingulate cortex (ACC). Only sparse phospho- α S-positive structures were observed in mice injected with Δ C10 seeds, Δ C20 seeds, and Δ C30 seeds, and these were restricted to Str, SN, and Amy in the injected hemisphere. On the contrary, abundant phospho- α S aggregates were observed throughout the bilateral brain, including Str, SN, Amy, and ACC, in mice injected with Δ N10 seeds and Δ N30 seeds. To evaluate the accumulated α S biochemically, we analyzed sarkosyl-insoluble fractions (Sar-ppt) from whole mouse brain (Fig. 2C). The amounts of insoluble phospho- α S in mice injected with Δ N10 seeds and Δ N30 seeds were larger than in mice injected with WT seeds, whereas only very faint bands were detected in mice injected with Δ C10 seeds, Δ C20 seeds, Δ C30 seeds, and Δ N20 seeds (Fig. 2D). These phospho- α S bands were stained with anti-mouse α S-specific antibody (D37A6), but not with anti-human α S-specific antibody (LB509). We also compared the amount of insoluble mouse α S but did not find any difference among the mice because of the high basal signal detected in mock-treated mice. These results indicate that N-terminal 10- or 30-residue truncation of human α S enhances the cross-seeding activity with WT mouse α S *in vivo*, despite the low seeding activity *in vitro* (Fig. 1D). On the other hand, the cross-seeding activities are reduced by C-terminal truncations and N-terminal 20-residue truncation.

Effect of truncation on seed-dependent aggregation of α S in cultured cells

To further confirm these differences, we compared the cross-seeding activities using a cultured cell model. SH-SY5Y cells transiently expressing mouse WT α S were transfected with human WT and truncated α S fibril seeds: Δ C20, Δ N10, Δ N20, and Δ N30 seeds. Two days after transfection, we checked the presence of insoluble α S aggregates in cells by biochemical fractionation and Western blot analysis (Fig. 3A). The levels of mouse α S in sarkosyl-insoluble fraction were increased in cells treated with α S fibril seeds, and the insoluble mouse α S bands were positive to anti-phospho- α S antibody (pSer-129/pSyn#64). The amount of insoluble phosphorylated α S in cells treated with Δ N30 seeds was larger than those in cells treated with WT seeds, whereas the amounts in cells treated with Δ N20 seeds and Δ C20 seeds were relatively small (Fig. 3B). We also compared the amount of insoluble mouse α S and found the amount of insoluble mouse α S in cells treated with Δ N30 seeds was larger than those in cells treated with WT seeds. Similar results were observed when SH-SY5Y cells overexpressing FLAG-human α S were treated with truncated fibril seeds (Fig. S2). These results indicate that human truncated α S fibrils can convert soluble mouse and human FL α S into insoluble form, and some N-terminal truncations have more potent cross-seeding activities in cultured cells.

Truncation induces fibril polymorphs of α S

As described above, N-terminal 10- or 30-residue truncation of human α S results in increased cross-seeding activity *in vivo*, suggesting that these truncations induce different fibrillar polymorphs. In this context, the protease digestion pattern reflect the structure of the cross- β sheet-rich fibril core region, and is commonly used to characterize the conformations of amyloid fibrils (27–29). Therefore, we compared the proteinase K (PK)-resistant fractions of truncated human α S fibrils with those of WT mouse α S fibrils. WT mouse α S fibrils (WT^{Mo} seed) showed \sim 10 and \sim 8 kDa PK-resistant fractions after PK digestion, whereas WT human α S fibrils (WT^{Hu} seed) yielded \sim 12 and \sim 8 kDa fractions (Fig. 4A). The N-terminally truncated human α S fibrils showed a WT mouse-like digestion pattern, suggesting that these fibrils share a common fibril core structure with WT mouse fibrils. In contrast, the Δ C20 fibrils showed a WT human-like digestion pattern. Next, we compared the digestion patterns of FL mouse α S aggregates (FLA^{Mo}) seeded with the α S fibrils. FL mouse α S aggregates obtained with WT^{Mo} seed (FLA^{Mo}-WT^{Mo}) showed \sim 10 and \sim 8 kDa resistant fractions after PK digestion, whereas aggregates with WT^{Hu} seed (FLA^{Mo}-WT^{Hu}) were digested into low-molecular fractions (Fig. 4B). FL mouse α S aggregates obtained with N-terminal truncated fibril seeds (FLA^{Mo}- Δ N10, Δ N20, and Δ N30) showed FLA^{Mo}-WT^{Mo}-like digestion patterns, whereas FLA^{Mo}- Δ C20 showed a FLA^{Mo}-WT^{Hu}-like pattern. These results imply that the N-terminal truncations of human α S have similar conformations to WT mouse α S fibrils, and can work as seeds for mouse α S monomer to form α S fibrils with structural properties similar to those of WT mouse α S fibrils.




Figure 2. Comparison of α S pathologies in WT mouse brains by inoculation of human WT and truncated α S fibril seeds. A, distributions of phospho- α S pathology in WT mouse brains. WT mice injected with human α S fibrils into the striatum were assessed at 3 months after injection. α S pathology was evaluated by immunohistochemistry with anti-pSer-129 antibody (EP1536Y). Sections were counterstained with hematoxylin. Representative images of ipsilateral striatum (Str), substantia nigra (SN), amygdala (Amy), and anterior cingulate cortex (ACC) of inoculated mice are shown. Scale bars, 25 μ m. B, quantification of phospho- α S pathology of each area (red, injection side; blue, contralateral side). Data are shown as mean percentage area occupied by pSer-129-positive structures \pm S.E. ($n = 3$ per group). N.D., not detected. *, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$. C, Western blot analysis of sarkosyl-soluble (sup) and sarkosyl-insoluble (ppt) fractions of injected brain extracts. The blots were probed using anti-pSer-129 (pSyn#64), anti-mouse α S specific (D37A6), anti-human α S specific (LB509), and anti-tubulin α antibodies. LB509, which recognizes 115–122 of human α S, cannot bind $\Delta C20$ and $\Delta C30$. Data are representative of three independent experiments. D, quantification of relative insoluble phospho- α S (upper) and mouse- α S (lower). Data presented are the means \pm S.E. ($n = 3$ per group). ***, $p < 0.001$.

N-terminal 10- and 30-residue-truncated human α S fibrils have decreased conformational stability

As described above, the N-terminal truncations of human α S form mouse α S-like fibrils, but sequential N-terminal truncations show biphasic seeding effects in mouse brain: Fibrils of

$\Delta N10$ and $\Delta N30$ have greater effects than fibrils of $\Delta N20$ (Fig. 2). In the prion field, there is a general consensus that seeding capacity is inversely related to fibril stability (30). Here, we examined the stability of the fibrils by treating WT and N-terminally truncated human α S fibrils with a chemical denaturant,




Figure 3. Cross-seeding activity of human WT and truncated α S fibrils in cultured cells. SH-SY5Y cells expressing WT mouse- α S were transfected with the α S fibril seeds. After 2 days, cells were collected, lysed with A68 buffer containing 1% sarkosyl, and fractionated. The supernatant (*sup*) and the pellet (*ppt*) fractions were subjected to Western blot analysis. *A*, Western blot analysis using anti-pSer-129 (pSyn#64), anti-mouse α S (D37A6), and anti-tubulin α antibodies. *B*, quantification of relative insoluble phospho- α S (*upper*) and mouse- α S (*lower*). Data presented are the means \pm S.E. ($n = 3$ per group). *, $p < 0.05$.




Figure 4. Concentration-dependent protease K digestion assays of α S aggregates. α S fibrils were treated with PK (0, 1, 10, 100 μ g/ml) for 30 min at 37 $^{\circ}$ C. After treatment, the samples were resolved using SDS-PAGE and stained by CBB. *A*, FL and truncated human α S fibril seeds. *B*, FL mouse α S aggregates seeded with mouse WT α S fibril seeds (WT^{Mo}), human WT α S fibril seeds (WT^{Hu}), and human truncated α S fibril seeds. A *filled circle* indicates the band at \sim 12 kDa; a *filled arrowhead* indicates the band at \sim 10 kDa; an *open arrowhead* indicates the band at \sim 8 kDa. Three independent experiments were done and representative data are shown.

sarkosyl, and separating the products into supernatant and pellet fractions by ultracentrifugation (Fig. 5). In the case of WT human α S, \sim 36% of the total protein was fractionated into the pellet ($36 \pm 4\%$ of total protein). The Δ N10 and Δ N30 fibrils, which could propagate efficiently in mouse brain, showed decreased conformational stability ($15 \pm 5\%$ and $19 \pm 6\%$ of total protein in the pellet, respectively). On the other hand, the Δ N20 fibrils, which exhibited inefficient seeding *in vivo*, showed increased stability ($58 \pm 3\%$ of total protein in the pellet). These results indicate that N-terminal 10- or 30-residue truncation enhances the cross-seeding activity *in vivo* as a result of decreased stability, implying that α S fibrils are propagated through a prion-like molecular mechanism.

C-terminal 20-residue truncation induces distinctive prion-like properties

Although Δ C20 fibrils showed drastically enhanced seeding activity *in vitro*, they induced only sparse α S pathology *in vivo* (Figs. 1D and 2). To investigate whether the apparent inconsistency is because of their structural characteristics, we analyzed the structures of the seeded FL α S aggregates (FLA)- Δ C20 *in vitro* and in cultured cells. TEM images showed that FLA seeded with Δ C20 seeds (FLA- Δ C20) had a twisted morphology that differed from the others, which showed straight, unbranched fibrillar structures with a diameter of \sim 10 nm (Fig. 6A; Fig. S3A). To explore the difference of the underlying structures, we quantified the ThT-binding properties of the seeded FL α S aggregates. FLA- Δ C20 showed higher binding affinity ($211 \pm 8\%$ of FLA-WT) (Fig. S3B). The rate of FL WT α S aggregation in the presence of FLA- Δ C20 was faster ($t_{1/2} = 5 \pm 0$ h) than that of FLA-WT^{Hu} ($t_{1/2} = 28 \pm 2$ h) (Fig. 6B). We also examined the seeding activities of the FL α S aggregates in cultured cells. FLA- Δ C20 showed poor seeding activity in cul-




Figure 5. Comparison of the stability of WT and N-terminal truncated α S fibrils. WT and N-terminally truncated α S fibrils were treated with 1% sarkosyl for 5 min at room temperature. The samples were centrifuged and the supernatant (S) and the pellet (P) fractions were analyzed by SDS-PAGE. The image of a gel stained with CBB (upper) and quantification data of α S protein (lower) are shown. Data presented are the means \pm S.E. percentage of α S protein in the pellet from five independent experiments. *, $p < 0.05$ compared with WT^{Hu}.

tured cells (Fig. 6, C and D). These results indicate that Δ C20 fibrils induce distinct structures of FL α S aggregates and these aggregates have similar but different seeding properties with Δ C20 fibrils *in vitro* and in cells (Figs. 1 and 3).

Discussion

Aggregation of α S can be influenced by mutations of *SNCA* gene (31–38), phosphorylation (39), and various other external conditions, including salt concentration (40, 41) and pH (42), during *in vitro* assembly. Human α S can be cleaved either at the N or C terminus by calpain 1 (16), plasmin (43), neurosin (44), 20S proteasome (19, 23), cathepsin D (45), caspase-1 (46), matrix metalloproteinase-3 (47), and asparagine endopeptidase (48), resulting in the production of a range of aggregation-prone truncated species (20, 49, 50). Our results show that C-terminal and N-terminal truncations not involved in the reported human α S fibril core region (residues 31–109) (28) induced fibril polymorphism characterized by different *in vitro* and *in vivo* propagation properties (Fig. 7).

The C-terminal region (residues 96–140) of α S is highly enriched in negatively charged residues (aspartate and glutamate) (51) and proline residues (52). Long-range interactions of the C-terminal region (residues 110–130) with the central hydrophobic NAC region (residues 85–95) (53, 54) are important to stabilize the natively unfolded structure (55–57). When the interaction between the C-terminal and the NAC region is weakened by low pH, addition of polycations, or changes in ionic strength, exposure of the NAC region increases, and more tightly packed α S fibrils are formed (50, 58). Tyrosine residues located at positions 125, 133, and 136 in the C-terminal region are crucial to maintain the N- and C-terminal intermolecular




Figure 6. C-terminal 20-residue truncation of human α S also produces distinctive prion-like properties. A, negative staining TEM imaging of human FL α S aggregates seeded with FL (left) or Δ C20 (right) seeds. Scale bars, 100 nm. Human FL α S aggregates seeded with Δ C20 seeds showed twisted fibrillar structure. B, aggregation kinetics of human FL α S monomers under quiescent conditions in the absence or presence of 1 mol % human FL α S aggregates seeded with WT or Δ C20 seeds, monitored by measuring ThT fluorescence. Data are averages of three samples. C, seed-dependent aggregation of α S induced by human FL α S aggregates seeded with WT or Δ C20 seeds in the cultured cell model. SH-SY5Y cells expressing FLAG- α S were transfected with α S monomer (FL Mono), human FL α S aggregates seeded with WT (FLA-WT), or Δ C20 (FLA- Δ C20). Cell extracts were prepared with A68 buffer containing 1% sarkosyl and centrifuged. The supernatant (sup) and the pellet (ppt) fractions were subjected to Western blot analysis using anti-pSer129 (pSyn#64), anti-FLAG, and anti-tubulin antibodies. D, the intensities of phosphorylated α S in (C) are quantified. ***, $p < 0.001$.

interactions and are related to aggregation (59). In addition to deletion of charged residues, complete removal of these tyrosine residues can result in structural polymorphisms. In the present study, the C-terminal 20-residue truncated fibrils showed enhanced seeding activity *in vitro*, and FLA seeded with Δ C20 seeds (FLA- Δ C20) exhibited twisted morphologies distinct from that of the original Δ C20 seeds and others, which showed straight structure. In our opinion, such twisted morphologies were likely caused by the negatively charged residues, which exist in FL monomers, but not in Δ C20 seeds. These

Truncation induces α -synuclein fibril polymorphs




Figure 7. Schematic representation of the effect of truncation on prion-like properties of α S. The N-terminal truncation of human α S changes the structure of the fibrils to a form similar to that of WT mouse α S fibrils. Furthermore, the N-terminally 10- or 30-residue-truncated human α S fibrils have lower conformational stability than WT human α S fibrils. As a result, these fibrils propagate effectively in WT mice. The C-terminally 20-residue-truncated fibrils show enhanced seeding activity *in vitro*, but reduced seeding activity in cell model and mouse model. There is no direct correlation between *in vitro* and *in vivo* propagation activities.

residues might interact with the core region of Δ C20 to form the twisted morphologies. As a result, C-terminal 20-residue truncated fibrils induced full-length α S polymorphisms.

The N-terminal region (residues 1–60) of human α S contains four imperfect 11-residue repeats with a conserved motif (XKTKEGVXXXX), which interacts with the lipid membrane, with conformational changes to the α -helical structure (26, 56). Although the N-terminal region directly interacts with the C-terminal region, but not the central NAC region, (57), N-terminal truncation also increases the ratio of β -sheet structure within α S fibrils (56). Recent studies have shown that familial PD-related mutations located in the N-terminal region influence the relative stability of the fibrils and their conformational preferences, rather than the global fibril structures (60, 61).

Truncation of the N-terminal 10 or 30 residues markedly enhanced cross-seeding activity in mouse brain. Structural compatibility between the seed and the host protein is important for cross-seeding activity *in vivo* (62). We found that N-terminal truncation switches the conformational preference of human α S fibrils, making them with structural properties similar to those of WT mouse α S fibrils, whereas C-terminal truncation does not have such an effect. Furthermore, we also found that N-terminal 10- or 30-residue truncation reduces conformational stability in a manner that is inversely correlated with *in vivo* propagation efficacy. Propagation of prion proteins depends on the stability of the pathogenic aggregates; less-stable prions replicate faster than more-stable prions (30). This would be another reason why these N-terminally truncated fibrils reduce the species barrier in WT mice. These results indicate that N-terminal truncation influences the prion-like seeding activity of α S.

As previously reported (62), we also found that propagation activities *in vitro*, in cells, and *in vivo* were not always consistent. In cultured cells, seeding reaction occurs in a more complex environment, such as molecular crowding, effects of chaperones and protein degradation machineries, other proteins interacting with seeds or monomers, and so on, compared with the simple reaction buffers used for *in vitro* assay (63). Moreover, seeds should be taken from outside of cells and escaped from endosomal vesicles if taken by endosome system in cultured cells. In mice, the cell to cell transmissibility might be

influenced by secretion and uptake of seeds (64). In this study, we found both Δ C20 seeds and FLA- Δ C20 seeds had markedly different seeding activities *in vitro* versus in cultured cells and mice. These seeds induced rapid aggregation *in vitro*, but not in cells and in mice. Contrary to these seeds, N-terminally truncated seeds such as Δ N30 induced severe pathology in cells and mice but had reduced seeding activity *in vitro*. These differences in propagation characteristics may result from different susceptibility of fibrils to external factors described above. It was reported that even α S fibrils that could not propagate effectively in WT mice might trigger α S pathology and neurodegeneration when proteolytic systems become less effective with aging (65) or in the presence of a genetic factor, such as heterozygous mutation in the lysosomal glucocerebrosidase gene (*GBA1*) (66, 67). Therefore, there is a possibility that Δ C20 seeds induce severe α S pathology in aged mice or lysosomal mutation mice. Consequently, it is important to evaluate the propagation properties of α S fibrils using multiple models.

In summary, our findings indicate that differently truncated human α S can induce various polymorphisms of FL α S fibrils via a seeding mechanism. The properties of N-terminal truncations of human α S imply that the pathogenicity of α S involves a prion-like molecular mechanism. We believe these findings provide new insights into both the pathogenicity and phenotypic diversity of sporadic α -synucleinopathies.

Experimental procedures

Antibodies

Antibodies used in the present study were anti-phospho- α S antibodies to pSer-129, including pSyn#64 (3) and EP1536Y (Abcam), and other anti- α S antibodies, including LB509 (a gift from Dr. Iwatsubo) and D37A6 (Cell Signaling Technology). Biotin-labeled secondary antibodies were purchased from Vector Laboratories for use in the avidin–biotin complex method.

Expression and purification of recombinant α S proteins

C-terminally truncated α S (Δ C10: residues 1–130, Δ C20: residues 1–120, and Δ C30: residues 1–110) and N-terminally truncated α S (Δ N10: residues 11–140, Δ N20: residues 21–140, and Δ N30: residues 31–140) were amplified by PCR with the following primers and subcloned into pRK172 (68, 69): Δ C10, forward, 5'-aggagatatacatatggatgtattcatgaa-3' and reverse, 5'-atcggaaattcaagcttttactcataaggcatttcat-3'; Δ C20, forward, 5'-aggagatatacatatggatgtattcatgaa-3' and reverse, 5'-atcggaaattcaagcttttactcataaggcatttcat-3'; Δ C30, forward, 5'-aggagatatacatatggatgtattcatgaa-3' and reverse, 5'-atcggaaattcaagcttttactcataaggcatttcat-3'; Δ N10, forward, 5'-aggagatatacatatggccaaggagggttgt-3' and reverse, 5'-atcggaaattcaagcttttaggcttcaggttctgt-3'; Δ N20, forward, 5'-aggagatatacatatgaaaaccaaacagggtgt-3' and reverse, 5'-atcggaaattcaagcttttaggcttcaggttctgt-3'; Δ N30, forward, 5'-aggagatatacatatgggaaagacaaaaggagg-3' and reverse, 5'-atcggaaattcaagcttttaggcttcaggttctgt-3'.

All constructs were verified by DNA sequencing. Recombinant proteins were expressed in *E. coli* BL21 (DE3) as described previously (70). Bacterial pellets were sonicated in extraction buffer A (50 mM Tris-HCl, pH 7.5, 1 mM EGTA, 1 mM DTT) on ice. The homogenates were centrifuged at 16,000 \times g for 15 min, and the supernatants were boiled for 5 min. Then, the

supernatants (heat-stable fraction) of 15-min centrifugation at $16,000 \times g$ were subjected to anion-exchange (for WT, Δ C10, Δ C20, Δ N10, Δ 20, and Δ N30) or cation-exchange (for Δ C30) chromatography on columns (Q Sepharose or SP Sepharose Fast Flow, respectively; GE Healthcare Japan) equilibrated with extraction buffer A. The columns were washed with extraction buffer A and eluted with a 100–500 mM NaCl gradient. The eluates were concentrated by precipitation with 50% saturated ammonium sulfate. The pellets were re-suspended in and dialyzed against 30 mM Tris-HCl, pH 7.5. The protein concentrations were determined by reversed phase-HPLC (RP-HPLC), using an Aquapore RP300 column (71). Purified α S samples were analyzed by 13.5% SDS-PAGE and stained with CBB. Gel images were recorded with a Gel DocTM EZ Imager (Bio-Rad).

Preparation of α S fibril seeds

α S fibrils were prepared as follows. Purified recombinant α S proteins were dissolved in 30 mM Tris-HCl, pH 7.5, containing 150 mM KCl and 0.1% NaN₃, to a final concentration of 150 μ M protein. The proteins were incubated at 37 °C under linear shaking at 200 rpm for 7 days. The assembled α S was collected by ultracentrifugation at $135,000 \times g$ for 20 min at 25 °C. The resultant pellets were re-suspended and sonicated in 30 mM, Tris-HCl, pH 7.5, on ice with an ultrasonic homogenizer (VP-5S, TAITEC) and ultracentrifuged again. The pellet was re-suspended and sonicated again in 30 mM Tris-HCl, pH 7.5. The proteins were dissolved in 6 M guanidine hydrochloride and their concentrations were determined by HPLC as described above.

Transmission EM

The α S fibrils were diluted in 30 mM Tris-HCl pH 7.5 to 15 μ M, plated on carbon-coated 300-mesh copper grids (Nissin EM), and stained with 2% (v/v) phosphotungstate. Micrographs were recorded on a JEM-1400Plus electron microscope (JEOL).

Thioflavin T-binding assay

The degree of fibrillation was measured in terms of thioflavin T fluorescence intensity, which is increased when ThT binds to amyloid-like fibrils. The α S proteins (7.5 μ M) were incubated with 20 μ M ThT in 30 mM Tris-HCl buffer, pH 7.5, for 30 min at 37 °C. Fluorometry was performed using a microplate reader (Varioskan[®] Flash, excitation 442 nm, emission 485 nm; Thermo Scientific) and normalized to the ThT intensity of WT α S fibrils.

α S aggregation assay

Full-length α S aggregation experiments were performed using a microplate reader (Varioskan[®] Flash, excitation 442 nm, emission 485 nm; Thermo Scientific) and monitored by measuring ThT fluorescence in the absence or presence of 1 mol % sonicated α S fibril seeds. All experiments were performed at 37 °C, under quiescent conditions in flat-bottomed 96-well black plates (Sumitomo Bakelite) sealed with MicroAmp Optical Adhesive Film (Applied Biosystems) to prevent evaporation. The reaction mixture consisted of 30 mM Tris-HCl (pH 7.5) containing 150 mM KCl, 0.1% NaN₃, and 20 μ M ThT. Protein concentration was 150 μ M unless otherwise indicated. During

experiments under quiescent conditions, ThT fluorescence change was read every 6 min.

Proteinase K digestion of α S fibrils

α S fibrils (1 mg/ml) in 30 mM Tris-HCl, pH 7.5, were incubated for 30 min at 37 °C in the presence of various concentrations of proteinase K (1, 10, and 100 μ g/ml; Promega). The reaction was stopped by boiling the mixture for 10 min. The samples were analyzed by 15–20% Tris-Tricine-SDS-PAGE; the gels were stained with CBB (28). Gel images were recorded with a Gel DocTM EZ Imager (Bio-Rad).

Conformational stability assay of α S fibrils

α S fibrils (1 mg/ml) were incubated in 30 mM Tris-HCl, pH 7.5, containing 1% sarkosyl (w/w) for 5 min at room temperature. After ultracentrifugation at $135,000 \times g$ for 20 min at 25 °C, the supernatant was collected as sarkosyl-soluble fraction, and the pellet was re-suspended in 1 \times SDS-PAGE buffer. The samples were analyzed by 15% Tris-Tricine-SDS-PAGE; the gels were stained with CBB (28). Gel images were recorded with a Gel DocTM EZ Imager (Bio-Rad). The band intensities were quantified using ImageJ software. Conformational stability was determined as the ratio of α S in the pellet to total α S (supernatant + pellet).

Cell culture, transfection of plasmids, and treatment of α S proteins

Human neuroblastoma SH-SY5Y cells were maintained at 37 °C in 5% CO₂ in DMEM/F12 medium (Sigma-Aldrich) with 10% fetal calf serum, penicillin-streptomycin-glutamine (Gibco), and Minimum Eagle's Medium Nonessential Amino Acid Solution (Gibco). Cells at a concentration of 1.5×10^5 cells/ml were cultured to ~30–50% confluence in collagen-coated 6-well plates and transfected with pcDNA3-WT mouse α S or pcDNA3-FLAG-human α S plasmids using X-tremeGENE 9 (Roche), followed by culture for 16 h. The cells were treated with final 150 nM α S proteins using MultiFectam (Promega), as previously described (72).

Immunocytochemistry

SH-SY5Y cells grown on collagen-coated coverslips were fixed with 4% paraformaldehyde and stained with the indicated primary antibodies at 1:1,000 dilution. After incubation for 1 h, cells were washed and treated with secondary antibodies (anti-rabbit IgG-conjugated Alexa Fluor 568 and anti-mouse IgG-conjugated Alexa Fluor 488; Invitrogen) and Hoechst 33324 (Sigma-Aldrich) to counterstain nuclear DNA. The cells were mounted and analyzed using a BZ-X710 (Keyence) and BZ-X analyzer (Keyence).

Biochemical analysis of cultured cells

After incubation for 2 days, cells were harvested by centrifugation ($1,800 \times g$, 5 min) and washed with PBS. The cellular proteins were extracted with 300 μ l of buffer A68 (10 mM Tris-HCl, pH 7.5, 1 mM EGTA, 10% sucrose, 0.8 M NaCl) containing final 1% sarkosyl (w/w) by sonication. After ultracentrifugation at $135,000 \times g$ for 20 min at 25 °C, the supernatant was collected as sarkosyl-soluble fraction, and the protein concentration was

Truncation induces α -synuclein fibril polymorphs

determined by BCA assay. The pellet was washed once with 300 μ l of buffer A68 containing 1% sarkosyl, and solubilized in 100 μ l of SDS-sample buffer. Both sarkosyl-soluble and -insoluble fractions were analyzed by immunoblotting with appropriate antibodies as indicated (73). The band intensities of insoluble phospho- α S and mouse- α S were quantified using ImageJ software. The relative amount of precipitate mouse- α S was calculated by insoluble mouse- α S divided by insoluble plus soluble mouse- α S. Data are expressed as -fold induction relative to that in the WT.

α S inoculation into mice

Ten-week-old male C57BL/6J mice were purchased from CLEA Japan, Inc. All experimental protocols were performed according to the recommendations of the Animal Care and Use Committee of Tokyo Metropolitan Institute of Medical Science. α S proteins (150 μ M, 5 μ l) were injected into the right striatum (anterior-posterior, 0.5 mm; medial-lateral, -2.0 mm; dorsal-ventral, -3.5 mm). Inoculation into mouse brain was performed as described previously (10).

Immunohistochemistry of mouse brains

Three months after inoculation, mice were deeply anesthetized with pentobarbital injection and sacrificed. The brain was perfused with 0.1 M PBS, followed by 10% formalin neutral buffer solution. After fixation, the dissected brain was embedded in paraffin and 5 μ m-thick serial sections were prepared. For antigen retrieval, sections were treated with 100% formic acid (Wako) for 5 min and washed under running tap water, then brought to a boil in 0.1 M sodium citrate buffer (pH 6.0) for 10 min, followed by cooling for 1 h. Immunohistochemistry with mAb EP1536Y (1:2,000) directed against α S phosphorylated at Ser-129 was performed as described previously (10). Sections were counterstained with hematoxylin. α S pathologies were analyzed with a BZ-X710 (Keyence) and quantified using a BZ-X analyzer (Keyence).

Biochemical analysis of mouse brains

Frozen whole mouse brains were homogenized in 20 volumes of buffer A68 containing final 2% sarkosyl (w/v), and incubated at 37 $^{\circ}$ C for 30 min. The brain homogenates were centrifuged at $9,460 \times g$ for 20 min at 25 $^{\circ}$ C, and then the supernatants were collected and ultracentrifuged at $135,000 \times g$ for 20 min at 25 $^{\circ}$ C. The pellets were washed with 30 mM Tris-HCl (pH 7.5) and ultracentrifuged as before. The pellet was once washed with 300 μ l of buffer A68 containing 1% sarkosyl, and solubilized in 100 μ l of SDS-sample buffer. Both sarkosyl-soluble and -insoluble fractions were analyzed by Western blotting with appropriate antibodies as indicated (10). The band intensities of insoluble phospho- α S and mouse- α S were quantified using ImageJ software. The relative amount of precipitate mouse- α S was calculated by insoluble mouse- α S divided by insoluble plus soluble mouse- α S. Data are expressed as -fold induction relative to that in the WT.

Statistical analysis

Graphs were created, and statistics were calculated in Prism ver. 5 (GraphPad Software, San Diego, CA). Multiple group

comparisons were made by one-way analysis of variance (ANOVA) followed by Tukey's post hoc test. Data are presented as mean \pm S.E. unless otherwise noted. Significance was determined at *, $p < 0.05$, **, $p < 0.01$, and ***, $p < 0.001$.

Author contributions—M. T., G. S., and M. H. conceptualization; M. T., G. S., T. N., F. K., and M. H. resources; M. T. and M. H. data curation; M. T., G. S., T. N., F. K., A. T., and M. H. formal analysis; M. T., G. S., T. N., F. K., and M. H. validation; M. T., G. S., and M. H. investigation; M. T., G. S., and M. H. visualization; M. T., G. S., T. N., F. K., and M. H. methodology; M. T., G. S., and M. H. writing-original draft; M. T., G. S., T. N., F. K., A. T., and M. H. writing-review and editing; G. S., T. N., F. K., A. T., and M. H. supervision; M. H. funding acquisition; M. H. project administration.

References

1. Ross, C. A., and Poirier, M. A. (2004) Protein aggregation and neurodegenerative disease. *Nat. Med.* **10**, (suppl.) S10–S17 [CrossRef Medline](#)
2. Spillantini, M. G., Schmidt, M. L., Lee, V. M., Trojanowski, J. Q., Jakes, R., and Goedert, M. (1997) α -Synuclein in Lewy bodies. *Nature* **388**, 839–840 [CrossRef Medline](#)
3. Fujiwara, H., Hasegawa, M., Dohmae, N., Kawashima, A., Masliah, E., Goldberg, M. S., Shen, J., Takio, K., and Iwatsubo, T. (2002) α -Synuclein is phosphorylated in synucleinopathy lesions. *Nat. Cell Biol.* **4**, 160–164 [CrossRef Medline](#)
4. Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V. M., Trojanowski, J. Q., Mann, D., and Iwatsubo, T. (2002) Phosphorylated α -synuclein is ubiquitinated in α -synucleinopathy lesions. *J. Biol. Chem.* **277**, 49071–49076 [CrossRef Medline](#)
5. Jucker, M., and Walker, L. C. (2013) Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. *Nature* **501**, 45–51 [CrossRef Medline](#)
6. Frost, B., and Diamond, M. I. (2010) Prion-like mechanisms in neurodegenerative diseases. *Nat. Rev. Neurosci.* **11**, 155–159 [CrossRef Medline](#)
7. Conway, K. A., Harper, J. D., and Lansbury, P. T. (1998) Accelerated *in vitro* fibril formation by a mutant α -synuclein linked to early onset Parkinson disease. *Nat. Med.* **4**, 1318–1320 [CrossRef Medline](#)
8. Volpicelli-Daley, L. A., Luk, K. C., Patel, T. P., Tanik, S. A., Riddle, D. M., Stieber, A., Meaney, D. F., Trojanowski, J. Q., and Lee, V. M. (2011) Exogenous α -synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. *Neuron* **72**, 57–71 [CrossRef Medline](#)
9. Luk, K. C., Song, C., O'Brien, P., Stieber, A., Branch, J. R., Brunden, K. R., Trojanowski, J. Q., and Lee, V. M. (2009) Exogenous α -synuclein fibrils seed the formation of Lewy body-like intracellular inclusions in cultured cells. *Proc. Natl. Acad. Sci. U.S.A.* **106**, 20051–20056 [CrossRef Medline](#)
10. Masuda-Suzukake, M., Nonaka, T., Hosokawa, M., Oikawa, T., Arai, T., Akiyama, H., Mann, D. M., and Hasegawa, M. (2013) Prion-like spreading of pathological α -synuclein in brain. *Brain* **136**, 1128–1138 [CrossRef Medline](#)
11. Watts, J. C., Giles, K., Oehler, A., Middleton, L., Dexter, D. T., Gentleman, S. M., DeArmond, S. J., and Prusiner, S. B. (2013) Transmission of multiple system atrophy prions to transgenic mice. *Proc. Natl. Acad. Sci. U.S.A.* **110**, 19555–19560 [CrossRef Medline](#)
12. Tu, P. H., Galvin, J. E., Baba, M., Giasson, B., Tomita, T., Leight, S., Nakajo, S., Iwatsubo, T., Trojanowski, J. Q., and Lee, V. M. (1998) Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α -synuclein. *Ann. Neurol.* **44**, 415–422 [CrossRef Medline](#)
13. Peelaerts, W., Bousset, L., Van der Perren, A., Moskalyuk, A., Pulizzi, R., Giugliano, M., Van den Haute, C., Melki, R., and Baekelandt, V. (2015) α -Synuclein strains cause distinct synucleinopathies after local and systemic administration. *Nature* **522**, 340–344 [CrossRef Medline](#)
14. Lee, S. J., and Masliah, E. (2015) Neurodegeneration: Aggregates feel the strain. *Nature* **522**, 296–297 [CrossRef Medline](#)

15. Prusiner, S. B., Woerman, A. L., Mordes, D. A., Watts, J. C., Rampersaud, R., Berry, D. B., Patel, S., Oehler, A., Lowe, J. K., Kravitz, S. N., Geschwind, D. H., Glidden, D. V., Halliday, G. M., Middleton, L. T., Gentleman, S. M., Grinberg, L. T., and Giles, K. (2015) Evidence for α -synuclein prions causing multiple system atrophy in humans with parkinsonism. *Proc. Natl. Acad. Sci. U.S.A.* **112**, E5308–E5317 [CrossRef Medline](#)
16. Baba, M., Nakajo, S., Tu, P. H., Tomita, T., Nakaya, K., Lee, V. M., Trojanowski, J. Q., and Iwatsubo, T. (1998) Aggregation of α -synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. *Am. J. Pathol.* **152**, 879–884 [Medline](#)
17. Muntané, G., Ferrer, I., and Martínez-Vicente, M. (2012) α -Synuclein phosphorylation and truncation are normal events in the adult human brain. *Neuroscience* **200**, 106–119 [CrossRef Medline](#)
18. Kellie, J. F., Higgs, R. E., Ryder, J. W., Major, A., Beach, T. G., Adler, C. H., Merchant, K., and Knierman, M. D. (2014) Quantitative measurement of intact α -synuclein proteoforms from post-mortem control and Parkinson's disease brain tissue by intact protein mass spectrometry. *Sci. Rep.* **4**, 5797 [CrossRef Medline](#)
19. Liu, C. W., Giasson, B. I., Lewis, K. A., Lee, V. M., Demartino, G. N., and Thomas, P. J. (2005) A precipitating role for truncated α -synuclein and the proteasome in α -synuclein aggregation: Implications for pathogenesis of Parkinson disease. *J. Biol. Chem.* **280**, 22670–22678 [CrossRef Medline](#)
20. Murray, I. V., Giasson, B. I., Quinn, S. M., Koppaka, V., Axelsen, P. H., Ischiropoulos, H., Trojanowski, J. Q., and Lee, V. M. (2003) Role of α -synuclein carboxy-terminus on fibril formation in vitro. *Biochemistry* **42**, 8530–8540 [CrossRef Medline](#)
21. Periquet, M., Fulga, T., Myllykangas, L., Schlossmacher, M. G., and Feany, M. B. (2007) Aggregated α -synuclein mediates dopaminergic neurotoxicity in vivo. *J. Neurosci.* **27**, 3338–3346 [CrossRef Medline](#)
22. Michell, A. W., Tofaris, G. K., Gossage, H., Tyers, P., Spillantini, M. G., and Barker, R. A. (2007) The effect of truncated human α -synuclein (1–120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. *Cell Transplant.* **16**, 461–474 [CrossRef Medline](#)
23. Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, T. M., Jäkälä, P., Hartmann, T., Price, D. L., and Lee, M. K. (2005) Aggregation promoting C-terminal truncation of α -synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 2162–2167 [CrossRef Medline](#)
24. Prasad, K., Beach, T. G., Hedreen, J., and Richfield, E. K. (2012) Critical role of truncated α -synuclein and aggregates in Parkinson's disease and incidental Lewy body disease. *Brain Pathol.* **22**, 811–825 [CrossRef Medline](#)
25. Serpell, L. C., Berriman, J., Jakes, R., Goedert, M., and Crowther, R. A. (2000) Fiber diffraction of synthetic α -synuclein filaments shows amyloid-like cross- β conformation. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 4897–4902 [CrossRef Medline](#)
26. Qin, Z., Hu, D., Han, S., Hong, D. P., and Fink, A. L. (2007) Role of different regions of α -synuclein in the assembly of fibrils. *Biochemistry* **46**, 13322–13330 [CrossRef Medline](#)
27. Yonetani, M., Nonaka, T., Masuda, M., Inukai, Y., Oikawa, T., Hisanaga, S., and Hasegawa, M. (2009) Conversion of wild-type α -synuclein into mutant-type fibrils and its propagation in the presence of A30P mutant. *J. Biol. Chem.* **284**, 7940–7950 [CrossRef Medline](#)
28. Miake, H., Mizusawa, H., Iwatsubo, T., and Hasegawa, M. (2002) Biochemical characterization of the core structure of α -synuclein filaments. *J. Biol. Chem.* **277**, 19213–19219 [CrossRef Medline](#)
29. Tsuji, H., Arai, T., Kametani, F., Nonaka, T., Yamashita, M., Suzukake, M., Hosokawa, M., Yoshida, M., Hatsuta, H., Takao, M., Saito, Y., Murayama, S., Akiyama, H., Hasegawa, M., Mann, D. M., and Tamaoka, A. (2012) Molecular analysis and biochemical classification of TDP-43 proteinopathy. *Brain* **135**, 3380–3391 [CrossRef Medline](#)
30. Legname, G., Nguyen, H. O., Peretz, D., Cohen, F. E., DeArmond, S. J., and Prusiner, S. B. (2006) Continuum of prion protein structures enciphers a multitude of prion isolate-specified phenotypes. *Proc. Natl. Acad. Sci. U.S.A.* **103**, 19105–19110 [CrossRef Medline](#)
31. Li, J., Uversky, V. N., and Fink, A. L. (2001) Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α -synuclein. *Biochemistry* **40**, 11604–11613 [CrossRef Medline](#)
32. Fredenborg, R. A., Rospigliosi, C., Meray, R. K., Kessler, J. C., Lashuel, H. A., Eliezer, D., and Lansbury, P. T., Jr. (2007) The impact of the E46K mutation on the properties of α -synuclein in its monomeric and oligomeric states. *Biochemistry* **46**, 7107–7118 [CrossRef Medline](#)
33. Ghosh, D., Sahay, S., Ranjan, P., Salot, S., Mohite, G. M., Singh, P. K., Dwivedi, S., Carvalho, E., Banerjee, R., Kumar, A., and Maji, S. K. (2014) The newly discovered Parkinson's disease associated Finnish mutation (A53E) attenuates α -synuclein aggregation and membrane binding. *Biochemistry* **53**, 6419–6421 [CrossRef Medline](#)
34. Giasson, B. I., Uryu, K., Trojanowski, J. Q., and Lee, V. M. (1999) Mutant and wild type human α -synucleins assemble into elongated filaments with distinct morphologies in vitro. *J. Biol. Chem.* **274**, 7619–7622 [CrossRef Medline](#)
35. Porcari, R., Proukakis, C., Waudby, C. A., Bolognesi, B., Mangione, P. P., Paton, J. F., Mullin, S., Cabrita, L. D., Penco, A., Relini, A., Verona, G., Vendruscolo, M., Stoppini, M., Tartaglia, G. G., Camilloni, C., Christodoulou, J., Schapira, A. H., and Bellotti, V. (2015) The H50Q mutation induces a 10-fold decrease in the solubility of α -synuclein. *J. Biol. Chem.* **290**, 2395–2404 [CrossRef Medline](#)
36. Fares, M. B., Ait-Bouziad, N., Dikiy, I., Mbefo, M. K., Jovičić, A., Kiely, A., Holton, J. L., Lee, S. J., Gitler, A. D., Eliezer, D., and Lashuel, H. A. (2014) The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α -synuclein, and enhances its secretion and nuclear localization in cells. *Hum. Mol. Genet.* **23**, 4491–4509 [CrossRef Medline](#)
37. Rospigliosi, C. C., McClendon, S., Schmid, A. W., Ramlall, T. F., Barré, P., Lashuel, H. A., and Eliezer, D. (2009) E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in α -synuclein. *J. Mol. Biol.* **388**, 1022–1032 [CrossRef Medline](#)
38. Bussell, R., Jr., and Eliezer, D. (2001) Residual structure and dynamics in Parkinson's disease-associated mutants of α -synuclein. *J. Biol. Chem.* **276**, 45996–46003 [CrossRef Medline](#)
39. Ma, M. R., Hu, Z. W., Zhao, Y. F., Chen, Y. X., and Li, Y. M. (2016) Phosphorylation induces distinct α -synuclein strain formation. *Sci. Rep.* **6**, 37130 [CrossRef Medline](#)
40. Bousset, L., Pieri, L., Ruiz-Arlandis, G., Gath, J., Jensen, P. H., Habenstein, B., Madiona, K., Olieric, V., Böckmann, A., Meier, B. H., and Melki, R. (2013) Structural and functional characterization of two α -synuclein strains. *Nat. Commun.* **4**, 2575 [CrossRef Medline](#)
41. Peelaerts, W., and Baekelandt, V. (2016) α -Synuclein strains and the variable pathologies of synucleinopathies. *J. Neurochem.* **139**, Suppl. 1, 256–274 [CrossRef Medline](#)
42. Buell, A. K., Galvagnion, C., Gaspar, R., Sparr, E., Vendruscolo, M., Knowles, T. P., Linse, S., and Dobson, C. M. (2014) Solution conditions determine the relative importance of nucleation and growth processes in α -synuclein aggregation. *Proc. Natl. Acad. Sci. U.S.A.* **111**, 7671–7676 [CrossRef Medline](#)
43. Kim, K. S., Choi, Y. R., Park, J. Y., Lee, J. H., Kim, D. K., Lee, S. J., Paik, S. R., Jou, I., and Park, S. M. (2012) Proteolytic cleavage of extracellular α -synuclein by plasmin: Implications for Parkinson disease. *J. Biol. Chem.* **287**, 24862–24872 [CrossRef Medline](#)
44. Iwata, A., Maruyama, M., Akagi, T., Hashikawa, T., Kanazawa, I., Tsuji, S., and Nukina, N. (2003) Alpha-synuclein degradation by serine protease neurosin: Implication for pathogenesis of synucleinopathies. *Hum. Mol. Genet.* **12**, 2625–2635 [CrossRef Medline](#)
45. Sevelever, D., Jiang, P., and Yen, S. H. (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of α -synuclein and generation of its carboxy-terminally truncated species. *Biochemistry* **47**, 9678–9687 [CrossRef Medline](#)
46. Wang, W., Nguyen, L. T., Burlak, C., Chegini, F., Guo, F., Chataway, T., Ju, S., Fisher, O. S., Miller, D. W., Datta, D., Wu, F., Wu, C. X., Landeru, A., Wells, J. A., Cookson, M. R., et al. (2016) Caspase-1 causes truncation and aggregation of the Parkinson's disease-associated protein α -synuclein. *Proc. Natl. Acad. Sci. U.S.A.* **113**, 9587–9592 [CrossRef Medline](#)
47. Sung, J. Y., Park, S. M., Lee, C. H., Um, J. W., Lee, H. J., Kim, J., Oh, Y. J., Lee, S. T., Paik, S. R., and Chung, K. C. (2005) Proteolytic cleavage of extracellular secreted α -synuclein via matrix metalloproteinases. *J. Biol. Chem.* **280**, 25216–25224 [CrossRef Medline](#)

Truncation induces α -synuclein fibril polymorphs

48. Zhang, Z., Kang, S. S., Liu, X., Ahn, E. H., Zhang, Z., He, L., Iuvone, P. M., Duong, D. M., Seyfried, N. T., Benskey, M. J., Manfredsson, F. P., Jin, L., Sun, Y. E., Wang, J. Z., and Ye, K. (2017) Asparagine endopeptidase cleaves α -synuclein and mediates pathologic activities in Parkinson's disease. *Nat. Struct. Mol. Biol.* **24**, 632–642 [CrossRef Medline](#)
49. Crowther, R. A., Jakes, R., Spillantini, M. G., and Goedert, M. (1998) Synthetic filaments assembled from C-terminally truncated α -synuclein. *FEBS Lett.* **436**, 309–312 [CrossRef Medline](#)
50. Hoyer, W., Cherny, D., Subramaniam, V., and Jovin, T. M. (2004) Impact of the acidic C-terminal region comprising amino acids 109–140 on α -synuclein aggregation in vitro. *Biochemistry* **43**, 16233–16242 [CrossRef Medline](#)
51. Levitan, K., Chereau, D., Cohen, S. I., Knowles, T. P., Dobson, C. M., Fink, A. L., Anderson, J. P., Goldstein, J. M., and Millhauser, G. L. (2011) Conserved C-terminal charge exerts a profound influence on the aggregation rate of α -synuclein. *J. Mol. Biol.* **411**, 329–333 [CrossRef Medline](#)
52. Meuvis, J., Gerard, M., Desender, L., Baekelandt, V., and Engelborghs, Y. (2010) The conformation and the aggregation kinetics of α -synuclein depend on the proline residues in its C-terminal region. *Biochemistry* **49**, 9345–9352 [CrossRef Medline](#)
53. Lee, H. J., and Lee, S. J. (2002) Characterization of cytoplasmic α -synuclein aggregates. Fibril formation is tightly linked to the inclusion-forming process in cells. *J. Biol. Chem.* **277**, 48976–48983 [CrossRef Medline](#)
54. Zibae, S., Jakes, R., Fraser, G., Serpell, L. C., Crowther, R. A., and Goedert, M. (2007) Sequence determinants for amyloid fibrillogenesis of human α -synuclein. *J. Mol. Biol.* **374**, 454–464 [CrossRef Medline](#)
55. McLean, P. J., and Hyman, B. T. (2002) An alternatively spliced form of rodent α -synuclein forms intracellular inclusions in vitro: Role of the carboxy-terminus in α -synuclein aggregation. *Neurosci. Lett.* **323**, 219–223 [CrossRef Medline](#)
56. Kessler, J. C., Rochet, J. C., and Lansbury, P. T., Jr. (2003) The N-terminal repeat domain of α -synuclein inhibits β -sheet and amyloid fibril formation. *Biochemistry* **42**, 672–678 [CrossRef Medline](#)
57. Bertoncini, C. W., Jung, Y. S., Fernandez, C. O., Hoyer, W., Griesinger, C., Jovin, T. M., and Zweckstetter, M. (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured α -synuclein. *Proc. Natl. Acad. Sci. U.S.A.* **102**, 1430–1435 [CrossRef Medline](#)
58. Fernández, C. O., Hoyer, W., Zweckstetter, M., Jares-Erijman, E. A., Subramaniam, V., Griesinger, C., and Jovin, T. M. (2004) NMR of α -synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. *EMBO J.* **23**, 2039–2046 [CrossRef Medline](#)
59. Ulrih, N. P., Barry, C. H., and Fink, A. L. (2008) Impact of Tyr to Ala mutations on α -synuclein fibrillation and structural properties. *Biochim. Biophys. Acta* **1782**, 581–585 [CrossRef Medline](#)
60. Xu, L., Ma, B., Nussinov, R., and Thompson, D. (2017) Familial mutations may switch conformational preferences in α -synuclein fibrils. *ACS Chem. Neurosci.* **8**, 837–849 [CrossRef Medline](#)
61. Uversky, V. N. (2017) Looking at the recent advances in understanding α -synuclein and its aggregation through the proteoform prism. *F1000Res* **6**, 525 [CrossRef Medline](#)
62. Luk, K. C., Covell, D. J., Kehm, V. M., Zhang, B., Song, I. Y., Byrne, M. D., Pitkin, R. M., Decker, S. C., Trojanowski, J. Q., and Lee, V. M. (2016) Molecular and biological compatibility with host α -synuclein influences fibril pathogenicity. *Cell Rep.* **16**, 3373–3387 [CrossRef Medline](#)
63. Oueslati, A., Ximerakis, M., and Vekrellis, K. (2014) Protein transmission, seeding and degradation: Key steps for α -synuclein prion-like propagation. *Exp. Neurobiol.* **23**, 324–336 [CrossRef Medline](#)
64. Sacino, A. N., Brooks, M. M., Chakrabarty, P., Saha, K., Khoshbouei, H., Golde, T. E., and Giasson, B. I. (2017) Proteolysis of α -synuclein fibrils in the lysosomal pathway limits induction of inclusion pathology. *J. Neurochem.* **140**, 662–678 [CrossRef Medline](#)
65. Vilchez, D., Saez, I., and Dillin, A. (2014) The role of protein clearance mechanisms in organismal ageing and age-related diseases. *Nat. Commun.* **5**, 5659 [CrossRef Medline](#)
66. Dehay, B., Martinez-Vicente, M., Caldwell, G. A., Caldwell, K. A., Yue, Z., Cookson, M. R., Klein, C., Vila, M., and Bezaud, E. (2013) Lysosomal impairment in Parkinson's disease. *Movement Disorders* **28**, 725–732 [CrossRef Medline](#)
67. Bae, E. J., Yang, N. Y., Lee, C., Lee, H. J., Kim, S., Sardi, S. P., and Lee, S. J. (2015) Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α -synuclein aggregation. *Exp. Mol. Med.* **47**, e188 [CrossRef Medline](#)
68. Masuda, M., Dohmae, N., Nonaka, T., Oikawa, T., Hisanaga, S., Goedert, M., and Hasegawa, M. (2006) Cysteine misincorporation in bacterially expressed human α -synuclein. *FEBS Lett.* **580**, 1775–1779 [CrossRef Medline](#)
69. Jakes, R., Spillantini, M. G., and Goedert, M. (1994) Identification of two distinct synucleins from human brain. *FEBS Lett.* **345**, 27–32 [CrossRef Medline](#)
70. Masuda, M., Suzuki, N., Taniguchi, S., Oikawa, T., Nonaka, T., Iwatsubo, T., Hisanaga, S., Goedert, M., and Hasegawa, M. (2006) Small molecule inhibitors of α -synuclein filament assembly. *Biochemistry* **45**, 6085–6094 [CrossRef Medline](#)
71. Nonaka, T., Iwatsubo, T., and Hasegawa, M. (2005) Ubiquitination of α -synuclein. *Biochemistry* **44**, 361–368 [CrossRef Medline](#)
72. Oikawa, T., Nonaka, T., Terada, M., Tamaoka, A., Hisanaga, S., and Hasegawa, M. (2016) α -Synuclein fibrils exhibit gain of toxic function, promoting tau aggregation and inhibiting microtubule assembly. *J. Biol. Chem.* **291**, 15046–15056 [CrossRef Medline](#)
73. Nonaka, T., Watanabe, S. T., Iwatsubo, T., and Hasegawa, M. (2010) Seeded aggregation and toxicity of α -synuclein and tau: Cellular models of neurodegenerative diseases. *J. Biol. Chem.* **285**, 34885–34898 [CrossRef Medline](#)